[PDF] Top 20 Fracturas del húmero proximal: su tratamiento con clavos bloqueados proximales
Has 10000 "Fracturas del húmero proximal: su tratamiento con clavos bloqueados proximales" found on our website. Below are the top 20 most common "Fracturas del húmero proximal: su tratamiento con clavos bloqueados proximales".
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer
... to enzalutamide therapy is more promi- nent in patient subgroups that have been previously treated with other chemotherapeutic drugs (Figure ...to enzalutamide may have developed multiple drug resistance, ... See full document
17
A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.
... resistant prostate cancer from androgen-sensitive prostate cancer have provided new avenues exploring efficacious therapies in a disease which is the second leading cause of ... See full document
39
Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies
... (NCT00417079) conducted in 755 patients with mCRPC previously treated with docetaxel; participants were random- ized to receive either cabazitaxel or mitoxantrone, both in combination with prednisone. The primary end ... See full document
5
Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
... 12 Antonarakis, E. S. et al. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. The oncologist, ... See full document
80
Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
... the treatment of mCRPC, and now also used for earlier ...next generation of inhibitors that directly bind to the ...of antiandrogen in the μg/mL range. At recommended doses for enzalutamide, ... See full document
6
Galeterone for the treatment of advanced prostate cancer: the evidence to date
... the treatment of metastatic castration- resistant prostate cancer, resulting in significant improvements in quality of life and survival with the use of several new agents, including the ... See full document
23
Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer
... These antiandrogen agents can be categorized as steroidal or ...adjuvant treatment, improved progression- free survival (PFS) in men with locally-advanced prostate cancer, but not in ... See full document
22
Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial
... which prostate cancer patients with less aggressive tumors on diagnosis defer immediate traditional conven- tional therapy (surgery, radiation) and undergo close monitoring by a physician for any clinical ... See full document
55
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
... generate enzalutamide resistant LNCaP in the study mentioned above [7] was different from our ...3 enzalutamide resistant sub-lines, suggesting AR overexpression as a common mechanism for ... See full document
7
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
... several second-generation AR signaling inhibitors have been successfully tested in patients with metastatic CRPC confirming that prostate cancer growth remains dependent on androgen ...novel ... See full document
19
The effectiveness of zoledronic acid and ibandronic acid as therapy for bone metastases in multiple myeloma: A systematic review
... the treatment of bone metastases compared with ibandronic ...latest cancer therapy guidelines recommend zoledronic acid for the early stages of MM with the recommended dose of 4 mg IV in 15 minutes of ... See full document
22
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
... trial, enzalutamide significantly increased overall survival (OS) for men with metastatic castration- resistant prostate cancer (mCRPC) after chemotherapy versus placebo and significantly decreased ... See full document
8
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
... anti-PD1 treatment failed to produce an objective response in a separate small trial of 17 CRPC patients ...other cancer types have suggested that the poor results testing anti-PD-1 therapy in CRPC may be ... See full document
98
Enzalutamide for patients with metastatic castration-resistant prostate cancer
... comparing enzalutamide with bicalutamide in men with early ...for enzalutamide compared to bicalutamide (hazard ratio, ...the enzalutamide group compared to ...of enzalutamide-treated patients ... See full document
5
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer
... localized prostate volume versus the same radiotherapy with 6 months of androgen suppression which was started 2 months before radiation and continued during radiation and then for 2 months after ...lower ... See full document
18
Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events
... Recent legislation in the United States and the European Union gave regulatory agencies the authority to require sponsors to conduct PASS as a condition of approval. The regulatory intent behind these required studies is ... See full document
6
Importance of antiresorptive therapies for patients with bone metastases from solid tumors
... with cancer. Medical care for patients with cancer requires a coordinated effort between primary care physicians and ...when cancer has metastasized to ...the advanced cancer ... See full document
11
Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology
... ‘ It is strongly suggested that external beam radiation (EBR) is bene fi cial for relief from pain ’ . EBR can relieve pain caused by bone metastasis without SpCC or patho- logical fracture in 59 – 73% of cases, 38–40 and ... See full document
10
Refractory hypercalcemia of malignancy related to vitamin D toxicity: Treatment strategies
... A second step in the work-up would be the measurement of the PTHrP ...various advanced malignancies involving bone ...of treatment and nearly daily IV fluid ... See full document
76
Impact of denosumab on bone mass in cancer patients
... breast cancer are SERMs, including tamoxifen, and in premenopausal women are oophorectomy and lutenizing hormone-releasing hormone (LHRH) agonists, including goserelin and ...breast cancer randomly assigned ... See full document
12
Related subjects